Dave Muoio
The updated version of the company's system includes automatic alerts when the wearer's glucose is too high or too low.
Device owners in participating states will soon receive enrollment notifications, while public health authorities may automatically have Exposure Notification apps generated for them.
The company said it has grown its business by 400% in the last three months alone.
Also: Abbott sells 150 million of its rapid, app-paired COVID-19 test to the White House; Platform launches for chronic disease patients juggling multiple providers.
The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.
The Stasis system tracks six vital signs, and so far has largely been deployed in India.
A frequent partner of biopharmas and the FDA, it has raised $94 million from investors since its commercial launch in 2015.
The raise reportedly brings the company's valuation into unicorn territory.
The deal joins each company's voice sample datasets to improve R&D, and helps Sonde collect more data across platforms.
Under the banner of the Consumer Technology Association, the companies hope that clear standards will improve digital therapeutics adoption and implementation.